Back
Compare AU
Compare VLUE vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck MSCI International Value ETF (VLUE) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
VLUE | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 81 | 73 |
Median incremental investment | $1,200.00 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $7,342.04 | $2,076.80 |
Average age group | > 35 | > 35 |
Key Summary
VLUE | DRUG | |
|---|---|---|
Strategy | VLUE.AX was created on 2021-03-08 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. VLUE.AX gives investors a diversified portfolio of 250 international developed market large- and mid-cap companies, with high value scores as calculated by MSCI at each rebalance. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Micron Technology Inc (4.90 %) Salesforce Inc (2.97 %) Kioxia Holdings Corp Ordinary Shares (2.23 %) | AUD - AUSTRALIA DOLLAR (0 %) BRL - BRAZILIAN REAL (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Information Technology (52.67 %) Communication Services (17.78 %) Other (14.84 %) | Other (75.91 %) Communication Services (33.53 %) Health Care (23.80 %) |
Top 3 countries | United States (45.12 %) Japan (22.90 %) United Kingdom of Great Britain and Northern Ireland (6.33 %) | United States (69.91 %) Switzerland (10.93 %) United Kingdom of Great Britain and Northern Ireland (7.38 %) |
Management fee | 0.4 % | 0.57 % |
Key Summary
VLUE | DRUG | |
|---|---|---|
Issuer | VanEck | BetaShares |
Tracking index | MSCI World ex Australia Index - AUD - Benchmark TR Net | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.4 % | 0.57 % |
Price | $38.44 | $8.80 |
Size | $637.145 million | $173.548 million |
10Y return | N/A | 82.19 % |
Annual distribution yield (5Y) | 6.23 % | 1.82 % |
Market | ASX | ASX |
First listed date | 09/03/2021 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
VLUE | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 81 | 73 |
Median incremental investment | $1,200.00 | $736.96 |
Median investment frequency | Monthly | Monthly |
Median total investment | $7,342.04 | $2,076.80 |
Average age group | > 35 | > 35 |
Pros and Cons
VLUE | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
VLUE | DRUG |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |